Literature DB >> 15143298

Insidious cognitive decline in CADASIL.

Kaarina Amberla1, Minna Wäljas, Susanna Tuominen, Ove Almkvist, Minna Pöyhönen, Seppo Tuisku, Hannu Kalimo, Matti Viitanen.   

Abstract

BACKGROUND AND
PURPOSE: Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) causes repeated ischemic attacks leading to subcortical vascular dementia. The aim of this study was to characterize cognitive function in subjects with a C475T (R133C) mutation in the Notch3 gene, leading to CADASIL.
METHODS: Prestroke (n=13) and poststroke (n=13) mutation carriers and mutation carriers with dementia (n=8) were compared with healthy noncarriers from the same families using a comprehensive set of neuropsychological tests.
RESULTS: Changes in working memory and executive function were observed in the very early phase of the disease before transient ischemic attack (TIA) or stroke. Later, in the poststroke phase, the cognitive impairment concerned also mental speed and visuospatial ability. Finally, the subjects with dementia had multiple cognitive deficits, which engaged even verbal functions, verbal episodic memory, and motor speed. The 2 mutation carrier groups without dementia and the controls could be reliably distinguished using 3 tests that assessed working memory/attention, executive function, and mental speed. Episodic memory was relatively well-preserved late in the disease.
CONCLUSIONS: A deterioration of working memory and executive function was already observed in the prestroke phase, which means that cognitive decline may start insidiously before the first onset of symptomatic ischemic episodes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143298     DOI: 10.1161/01.STR.0000129787.92085.0a

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  18 in total

1.  Cognitive profile in CADASIL patients.

Authors:  L Caeiro; J M Ferro
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

Review 2.  Single gene disorders causing ischaemic stroke.

Authors:  Saif S M Razvi; Ian Bone
Journal:  J Neurol       Date:  2006-06       Impact factor: 4.849

3.  Cognitive profile in CADASIL.

Authors:  F Buffon; R Porcher; K Hernandez; A Kurtz; S Pointeau; K Vahedi; M-G Bousser; H Chabriat
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

4.  Treatment of Vascular Cognitive Impairment.

Authors:  Aaron Ritter; Jagan A Pillai
Journal:  Curr Treat Options Neurol       Date:  2015-08       Impact factor: 3.598

5.  Clinical presentation of CADASIL in an Italian patient with a rare Gly528Cys exon 10 NOTCH3 gene mutation.

Authors:  M Ragno; G Cacchiò; G M Fabrizi; M Scarcella; F Silvaggio; T Cavallaro; F Taioli; L Trojano
Journal:  Neurol Sci       Date:  2007-08-10       Impact factor: 3.307

Review 6.  Neuropsychiatric manifestations in CADASIL.

Authors:  Hugues Chabriat; Marie-Germaine Bousser
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

7.  Impairments in Episodic-Autobiographical Memory and Emotional and Social Information Processing in CADASIL during Mid-Adulthood.

Authors:  Angelica Staniloiu; Friedrich G Woermann; Hans J Markowitsch
Journal:  Front Behav Neurosci       Date:  2014-06-25       Impact factor: 3.558

8.  Case report: bipolar disorder as the first manifestation of CADASIL.

Authors:  Soyeon Park; Boram Park; Min Kyung Koh; Yeon Ho Joo
Journal:  BMC Psychiatry       Date:  2014-06-14       Impact factor: 3.630

9.  Notch3-Dependent Effects on Adult Neurogenesis and Hippocampus-Dependent Learning in a Modified Transgenic Model of CADASIL.

Authors:  Fanny Ehret; Ricardo Moreno Traspas; Marie-Theres Neumuth; Bianca Hamann; Daniela Lasse; Gerd Kempermann
Journal:  Front Aging Neurosci       Date:  2021-05-21       Impact factor: 5.750

10.  Role of Notch signaling in neurovascular aging and Alzheimer's disease.

Authors:  Arunima Kapoor; Daniel A Nation
Journal:  Semin Cell Dev Biol       Date:  2020-12-28       Impact factor: 7.499

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.